Gyre Therapeutics (NASDAQ:GYRE) Sees Large Volume Increase – Still a Buy?

Gyre Therapeutics, Inc. (NASDAQ:GYRE – Get Free Report) saw strong trading volume on Monday. Approximately 124,635 shares traded hands during trading, an increase of 14% from the average daily volume of 109,507 shares. The stock last traded at $4.76 and had previously closed at $4.31.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on GYRE. Wall Street Zen raised Gyre Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, November 7th. Zacks Research raised shares of Gyre Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Tuesday, October 6th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Gyre Therapeutics in a report on Wednesday, November 4th. One analyst has rated the stock with a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Gyre Therapeutics has an average rating of “Reduce”.

View Our Latest Stock Analysis on GYRE

Gyre Therapeutics Stock Performance

The firm’s 50 day moving average price is $6.20 and its 200-day moving average price is $6.78. The firm has a market capitalization of $525.86 million, a PE ratio of -22.80 and a beta of 2.14.

Gyre Therapeutics (NASDAQ:GYRE – Get Free Report) last posted its earnings results on Thursday, November 5th. The company reported $0.04 EPS for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.19. The firm had revenue of $32.93 million for the quarter, compared to analysts’ expectations of $28.40 million. Gyre Therapeutics had a negative return on equity of 7.39% and a negative net margin of 14.80%. On average, equities research analysts expect that Gyre Therapeutics, Inc. will post -0.61 earnings per share for the current fiscal year.

Institutional Trading of Gyre Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the business. BlackRock Inc. acquired a new stake in Gyre Therapeutics in the 2nd quarter valued at $6,550,000. Bank of New York Mellon Corp purchased a new stake in Gyre Therapeutics in the 2nd quarter worth $414,000. Deutsche Bank AG purchased a new stake in Gyre Therapeutics in the 2nd quarter worth $118,000. Dimensional Fund Advisors LP increased its holdings in Gyre Therapeutics by 131.8% in the 1st quarter. Dimensional Fund Advisors LP now owns 25,268 shares of the company’s stock worth $176,000 after acquiring an additional 14,365 shares in the last quarter. Finally, Bank of America Corp DE acquired a new position in Gyre Therapeutics during the second quarter worth $83,000. 23.99% of the stock is currently owned by hedge funds and other institutional investors.

About Gyre Therapeutics

(Get Free Report)

Gyre Therapeutics is a biopharmaceutical company focused on developing and commercializing treatments for liver and other chronic diseases. The company operates in the United States and China, including through its China-based subsidiary, Beijing Continent Pharmaceuticals. Its pipeline includes hydronidone, also known as F351, an oral drug candidate being developed for liver fibrosis associated with chronic hepatitis B. Gyre is also developing treatments for other serious conditions, including acute-on-chronic liver failure.

Recommended Stories

Receive News & Ratings for Gyre Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gyre Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.